Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators.

Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30.

PMID:
25271206
2.

Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice.

Thiel A, Narko K, Heinonen M, Hemmes A, Tomasetto C, Rio MC, Haglund C, Mäkelä TP, Ristimäki A.

Int J Cancer. 2012 Sep 1;131(5):1032-41. doi: 10.1002/ijc.27331. Epub 2011 Dec 14.

3.

PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.

Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, Hla T.

Prostaglandins Other Lipid Mediat. 2009 Apr;88(3-4):97-100. doi: 10.1016/j.prostaglandins.2008.11.004. Epub 2008 Dec 24.

4.

VEGF-C and COX-2 expression in papillary thyroid cancer.

Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R, Haglund C.

Endocr Relat Cancer. 2006 Jun;13(2):465-73.

PMID:
16728574
5.

COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.

Narko K, Zweifel B, Trifan O, Ristimäki A, Lane TF, Hla T.

Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):86-94.

PMID:
15967164
6.

Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.

Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A.

Cancer Res. 2005 Mar 15;65(6):2157-61.

7.

Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.

Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimäki A.

Cancer Res. 2003 Jun 15;63(12):3032-6.

8.

[Cyclo-oxygenase 2 in cancer].

Saukkonen K, Narko K, Ristimäki A.

Duodecim. 1999;115(8):855-6. Finnish. No abstract available.

PMID:
11859518
9.

Regulated expression of prostaglandin E(2) receptors EP2 and EP4 in human ovarian granulosa-luteal cells.

Narko K, Saukkonen K, Ketola I, Bützow R, Heikinheimo M, Ristimäki A.

J Clin Endocrinol Metab. 2001 Apr;86(4):1765-8.

PMID:
11297615
10.

Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.

Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T.

J Biol Chem. 2001 May 25;276(21):18563-9. Epub 2001 Mar 7.

11.

Expression of cyclooxygenase-2 and prostanoid receptors by human myometrium.

Erkinheimo TL, Saukkonen K, Narko K, Jalkanen J, Ylikorkala O, Ristimäki A.

J Clin Endocrinol Metab. 2000 Sep;85(9):3468-75.

PMID:
10999850
12.

Effect of inflammatory cytokines on the expression of the vascular endothelial growth factor-C.

Narko K, Enholm B, Mäkinen T, Ristimäki A.

Int J Exp Pathol. 1999 Jun;80(3):109-12. Review. No abstract available.

13.

Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C.

Ristimäki A, Narko K, Enholm B, Joukov V, Alitalo K.

J Biol Chem. 1998 Apr 3;273(14):8413-8.

14.
15.
16.

Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression.

Narko K, Ristimäki A, MacPhee M, Smith E, Haudenschild CC, Hla T.

J Biol Chem. 1997 Aug 22;272(34):21455-60.

19.

Structure of the human cyclo-oxygenase-2 gene.

Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T.

Biochem J. 1994 Sep 15;302 ( Pt 3):723-7.

20.

[Gene defects in congenital adrenal hyperplasia in Finnish patients].

Partanen J, Narko K.

Duodecim. 1993;109(6):512-7. Review. Finnish. No abstract available.

PMID:
8062719

Supplemental Content

Support Center